	US 12,006,549 B2
	Methods utilizing leukocyte RNA expression in prognosis evaluation of medical interventions for epilepsy
Martin E. Weinand, Tucson, AZ (US); Ryan Sprissler, Tucson, AZ (US); and Michael F. Hammer, Tucson, AZ (US)
Assigned to ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, Tucson, AZ (US)
Appl. No. 17/269,092
Filed by Arizona Board of Regents on behalf of the University of Arizona, Tucson, AZ (US)
PCT Filed Oct. 4, 2019, PCT No. PCT/US2019/054733 § 371(c)(1), (2) Date Feb. 17, 2021, PCT Pub. No. WO2020/072926, PCT Pub. Date Apr. 9, 2020.
Claims priority of provisional application 62/741,719, filed on Oct. 5, 2018.
Prior Publication US 2021/0246509 A1, Aug. 12, 2021
Int. Cl. C12Q 1/68 (2018.01); C12Q 1/686 (2018.01); C12Q 1/6883 (2018.01); A61N 7/00 (2006.01)

CPC C12Q 1/6883 (2013.01) [C12Q 1/686 (2013.01); A61N 7/00 (2013.01); C12Q 2600/158 (2013.01); G01N 2800/2857 (2013.01); G01N 2800/52 (2013.01)]

4 Claims

1. A method of treating a subject with intractable epilepsy, comprising the steps of:

a) obtaining RNA from leukocytes from the subject;

b) based on the RNA present in the leukocytes, determining an expression level of 24 genes consisting of: FAM155A, ABCA4, ZFP57, IFI27, C5orf17, PLP1, PVRL2, FAM118A, GFAP, CDYL, CPEB4, FADS2, RSAD2, BIN3, BRSK1, AKAP7, IL22RA1, BGN, MMP8, PF4VI, MDGA1, ALOX15B, HBG1, and B4GALNT3;

c) comparing the determined expression level with a control expression level for each gene;

d) detecting upregulation of FAM155A, ABCA4, ZFP57, IFI27, C5orf17, PLP1, PVRL2, FAM118A, GFAP, CDYL, CPEB4, FADS2, RSAD2, BIN3, BRSK1, and AKAP7, and detecting downregulation of IL22RA1, BGN, MMP8, PF4VI, MDGA1, ALOX15B, HBG1, and B4GALNT3 relative to the control expression level for each gene; and

e) treating the subject with ablation treatment.